The North American IBD market is estimated to grow significantly at a CAGR of around 4.8% during the forecast period. Rising prevalence and incidence of IBD across the region is the major driving factor for the market. Moreover, an increasing number of cigarette-smokers in the US and significant funding in the IBD field in Canada is further estimated to boost the market growth of the region. Furthermore, well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across the region will support the market growth over the forecast period. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per Crohn’s and Colitis Canada (CCC), in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease, 120,000 with ulcerative colitis, and 15,000 with IBD type unclassified (IBD-U). CCC further estimates that seven out of every 1,000 Canadians have IBD. Moreover, by 2030, the number of people living with IBD is expected to rise to over 400,000, or nearly 1% of the population.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/north-american-ibd-inflammatory-bowel-disease-market
North American IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. North American IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/north-american-ibd-inflammatory-bowel-disease-market
The companies which are contributing to the growth of the North American IBD market include Abbott Laboratories, AbbVie Inc., Accesa Labs, Celgene Corp., Eli Lilly and Co., Johnson & Johnson Services Inc., Laboratory Corporation of America Holdings, Pfizer Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Market Segmentation
North American IBD Market by Disease Type
- Ulcerative Colitis
- Crohn’s Disease
North American IBD Market by Diagnostics
- Blood and Stool Tests
- Endoscopies,
- Ultrasound
- X-Ray
North American IBD Market by Therapeutics
- Surgery
- Anti- Inflammatory Drug Administration
- Steroids
- Immunosuppressant
- Biological Drugs
- Amino salicylates
- Others
Regional Analysis
- United States
- Canada
Company Profiles
- Abbott Laboratories
- AbbVie Inc.
- Accesa Labs
- Boehringer Ingelheim International GmbH
- Celgene Corp.
- Eli Lilly and Co.
- Johnson & Johnson Services Inc.
- Laboratory Corporation of America Holdings
- Pfizer Inc.
- Sanofi S.A.
- Takeda pharmaceutical Co., Ltd.
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
